Tags

Type your tag names separated by a space and hit enter

A double-blind, placebo-controlled study of memantine in the treatment of major depression.
Am J Psychiatry. 2006 Jan; 163(1):153-5.AJ

Abstract

OBJECTIVE

This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans.

METHOD

In a double-blind, placebo-controlled study, 32 subjects with major depression were randomly assigned to receive memantine (5-20 mg/day) (N=16) or placebo (N=16) for 8 weeks. Primary efficacy was assessed by performance on the Montgomery-Asberg Depression Rating Scale (MADRS).

RESULTS

The linear mixed models for total MADRS scores showed no treatment effect.

CONCLUSIONS

In an 8-week trial, the low-to-moderate-affinity NMDA antagonist memantine in doses of 5-20 mg/day was not effective in the treatment of major depressive disorder.

Authors+Show Affiliations

Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Human Health Services, Bethesda, MD, USA. zaratec@mail.nih.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Intramural

Language

eng

PubMed ID

16390905

Citation

Zarate, Carlos A., et al. "A Double-blind, Placebo-controlled Study of Memantine in the Treatment of Major Depression." The American Journal of Psychiatry, vol. 163, no. 1, 2006, pp. 153-5.
Zarate CA, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153-5.
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006). A double-blind, placebo-controlled study of memantine in the treatment of major depression. The American Journal of Psychiatry, 163(1), 153-5.
Zarate CA, et al. A Double-blind, Placebo-controlled Study of Memantine in the Treatment of Major Depression. Am J Psychiatry. 2006;163(1):153-5. PubMed PMID: 16390905.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A double-blind, placebo-controlled study of memantine in the treatment of major depression. AU - Zarate,Carlos A,Jr AU - Singh,Jaskaran B, AU - Quiroz,Jorge A, AU - De Jesus,Georgette, AU - Denicoff,Kirk K, AU - Luckenbaugh,David A, AU - Manji,Husseini K, AU - Charney,Dennis S, PY - 2006/1/5/pubmed PY - 2006/3/9/medline PY - 2006/1/5/entrez SP - 153 EP - 5 JF - The American journal of psychiatry JO - Am J Psychiatry VL - 163 IS - 1 N2 - OBJECTIVE: This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans. METHOD: In a double-blind, placebo-controlled study, 32 subjects with major depression were randomly assigned to receive memantine (5-20 mg/day) (N=16) or placebo (N=16) for 8 weeks. Primary efficacy was assessed by performance on the Montgomery-Asberg Depression Rating Scale (MADRS). RESULTS: The linear mixed models for total MADRS scores showed no treatment effect. CONCLUSIONS: In an 8-week trial, the low-to-moderate-affinity NMDA antagonist memantine in doses of 5-20 mg/day was not effective in the treatment of major depressive disorder. SN - 0002-953X UR - https://www.unboundmedicine.com/medline/citation/16390905/A_double_blind_placebo_controlled_study_of_memantine_in_the_treatment_of_major_depression_ L2 - https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.163.1.153?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -